^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastric Cancer
    Drug:PF-06804103 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

    Excerpt:
    ...- HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which...
    Trial ID:
    NCT03284723
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.

    Excerpt:
    In Part 1, groups of adult patients (pts) with HER2+ BC or HER2+ GC, who are resistant or intolerant to standard therapy or for which no standard therapy is available, received PF-06804103 intravenously once every 21 days (Q3W)...Preliminary ORR in the patients treated with doses ≥3mg/kg was 52.4% (11/21)....The PF-06804103 ADC demonstrated manageable toxicity and promising anti-tumor activity in this small, heavily pretreated study population.
    DOI:
    10.1200/JCO.2020.38.15_suppl.1039
    Trial ID:
    NCT03284723